Glypressin

Glypressin is an injectable solution that contains the active ingredient terlipressin acetate. It is supplied in a sterile vial for intravenous administration and is classified as a vasopressin analog. Glypressin is marketed in the European Union and is available only by prescription. The medication works as a selective V1 receptor agonist, producing vasoconstriction that helps manage specific complications of severe liver disease.

Glypressin is prescribed for conditions where rapid reduction of portal venous pressure is required. It is used under medical supervision in hospital settings for the following indications:

- Acute variceal bleeding associated with portal hypertension, to control hemorrhage. - Hepatorenal syndrome type 1, to improve renal perfusion. - Management of refractory hypotension in septic shock when other vasopressors are insufficient. - As a bridge therapy before definitive procedures such as transjugular intrahepatic portosystemic shunt (TIPS). - In clinical trials evaluating its efficacy for other portal hypertension complications.

Side effects of Glypressin vary in frequency and severity. Patients should be monitored for both common and serious adverse reactions.

Common: - Headache or dizziness due to transient blood pressure changes. - Nausea, vomiting, or abdominal discomfort. - Peripheral ischemia manifested as cold extremities or mild discoloration.

Serious: - Severe hypertension leading to hypertensive crisis. - Cardiac arrhythmias, including tachycardia or bradycardia. - Ischemic complications such as myocardial infarction or intestinal ischemia. - Acute renal failure secondary to excessive vasoconstriction. - Allergic reactions ranging from rash to anaphylaxis.

Before initiating Glypressin therapy, clinicians should assess patient-specific risk factors and monitor for potential complications. Important precautions include:

- Evaluate cardiovascular status; avoid use in uncontrolled hypertension or recent myocardial infarction. - Assess renal function; dose adjustment may be needed in severe renal impairment. - Use cautiously in patients with peripheral vascular disease or a history of ischemic events. - Monitor electrolytes, especially serum sodium and potassium, during treatment. - Discontinue if signs of severe vasoconstriction, such as limb ischemia, develop. - Pregnancy and lactation status are unknown; weigh potential benefits against risks.

Glypressin may interact with other medications, altering its efficacy or safety profile. Consider the following interaction guidance:

Avoid: - Concurrent use with other potent vasoconstrictors (e.g., norepinephrine) that may exacerbate hypertension. - Combination with monoamine oxidase inhibitors (MAOIs) that can increase vasoactive effects. - Co-administration with drugs that significantly prolong the QT interval.

Use with caution: - Concurrent diuretics, which may affect intravascular volume and renal perfusion. - Beta‑blockers, as they can mask tachycardia associated with vasoconstriction. - Anticoagulants, because changes in portal pressure may influence bleeding risk. - Sedatives or anesthetics, which may compound hypotensive or hypertensive responses.